<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02305186</url>
  </required_header>
  <id_info>
    <org_study_id>17801</org_study_id>
    <nct_id>NCT02305186</nct_id>
  </id_info>
  <brief_title>Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer</brief_title>
  <acronym>UVA-PC-PD101</acronym>
  <official_title>A Randomized Multicenter Phase Ib/II Study to Assess the Safety and the Immunological Effect of Chemoradiation Therapy (CRT) in Combination With Pembrolizumab (MK-3475) Compared to CRT Alone in Patients With Resectable or Borderline Resectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Craig L Slingluff, Jr</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to study an experimental drug called pembrolizumab or
      MK-3475 for use in combination with chemotherapy and radiation therapy for patients with
      resectable (surgical removal) or borderline resectable pancreatic cancer. In general,
      pancreatic cancer that cannot be removed by surgery is sometimes treated with chemotherapy
      and radiation therapy, called neoadjuvant treatment, to shrink the tumor so that surgery
      might be possible. However, this is not always effective at shrinking the tumor enough to
      allow it to be removed with surgery. Recent discoveries suggest that the investigators own
      immune system might have a role in controlling the growth of tumors. Drugs such as
      pembrolizumab can stimulate the immune system against cancer. The purpose of this study is to
      investigate whether pembrolizumab can be used safely during neoadjuvant treatment and can
      improve the body's immune response against pancreatic cancer.

      Pembrolizumab has been approved for treatment of patients with melanoma but has not been
      proven to be safe or helpful in patients with pancreatic cancer and is not approved by the
      U.S. Food and Drug Administration (FDA) for this purpose.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Tumor Infiltrating Lymphocytes (TILs) per high powered field (hpf) in pancreatic tissue (resected tissue).</measure>
    <time_frame>2-3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Incidence of Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>2-3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>2-4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2-4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate (RR)</measure>
    <time_frame>2-3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Neodjuvant CRT + Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard neoadjuvant chemoradiation treatment (CRT) with pembrolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant CRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard neoadjuvant chemoradiation treatment (CRT) alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab administered at a dose of 200 mg IV every 3 weeks on days 1, 22, and 43 during concurrent neoadjuvant chemoradiation treatment</description>
    <arm_group_label>Neodjuvant CRT + Pembrolizumab</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Neoadjuvant Chemoradiation</intervention_name>
    <description>Chemoradiation with capecitabine (825 mg/m2 orally twice daily, Monday through Friday, on days of radiation only) and radiation (50.4 Gy in 28 fractions over 28 days)</description>
    <arm_group_label>Neodjuvant CRT + Pembrolizumab</arm_group_label>
    <arm_group_label>Neoadjuvant CRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.

          2. Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
             Performance Scale

          3. Adequate organ function

          4. In subjects requiring biliary decompression, metal stent or drainage using
             percutaneous transhepatic cholangiogram (PTC) are allowed

        Exclusion Criteria:

          1. Immunodeficiency or taking steroid or any other form of immunosuppressive therapy

          2. Has a plastic biliary stent for decompression

          3. Metastatic disease

          4. Prior treatment for pancreatic cancer or prior treatment with radiation for other
             diagnoses to the expected pancreatic cancer treatment area

          5. Active autoimmune disease

          6. Pregnancy or Nursing

          7. Known history of Human Immunodeficiency Virus (HIV) or Hepatitis B or C

          8. Prior monoclonal antibody within 4 weeks prior to study Day 1

          9. Known additional malignancy that is progressing or requires active treatment

         10. Evidence of interstitial lung disease or active, non-infectious pneumonitis

         11. Active infection requiring systemic therapy

         12. Prior therapy with an anti-Program Death (PD-1) antibody, anti-PD-L1, anti-PD-L2, or
             anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Osama Rahma, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Camblos</last_name>
    <phone>434-243-1927</phone>
    <email>akc4c@virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steve Fowler</last_name>
    <phone>434-243-4730</phone>
    <email>saf2qh@virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Cianferra</last_name>
      <phone>305-243-1139</phone>
      <email>ecianferra@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Nicolas Acquavella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Schuetz</last_name>
      <phone>617-632-5575</phone>
      <email>SamanthaR_Schuetz@dfci.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Osama Rahma, MD</last_name>
      <email>OsamaE_Rahma@DFCI.HARVARD.EDU</email>
    </contact_backup>
    <investigator>
      <last_name>Osama Rahma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betty Taylor</last_name>
      <phone>713-792-3949</phone>
      <email>bjtaylor@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Matthew Katz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gauri Varadhachary, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Kelly</last_name>
      <phone>434-982-6584</phone>
      <email>SLK6VJ@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Todd Bauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2014</study_first_submitted>
  <study_first_submitted_qc>November 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2014</study_first_posted>
  <last_update_submitted>August 31, 2017</last_update_submitted>
  <last_update_submitted_qc>August 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Craig L Slingluff, Jr</investigator_full_name>
    <investigator_title>Director of the UVA Human Immune Therapy Center</investigator_title>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Neoadjuvant</keyword>
  <keyword>Resectable</keyword>
  <keyword>Borderline resectable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

